quarta-feira, 18 de maio de 2016

AstraZeneca's Lynparza fails in gastric cancer combination test | Daily Mail Online

Uma "pequena" janela para os "dramas" da indústria:

AstraZeneca's Lynparza fails in gastric cancer combination test | Daily Mail Online


Citando:

"AstraZeneca's recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday.

The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings."